Welcome to our dedicated page for NDYN news (Ticker: NDYN), a resource for investors and traders seeking the latest updates and insights on NDYN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NDYN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NDYN's position in the market.
Vinings Holdings (OTC PINK: NDYN) announced it will change its corporate name to Coeptis Therapeutics, Inc. and update its ticker symbol to COEP effective July 12, 2021. This rebranding aligns with the company's focus on developing innovative therapeutics through its subsidiary, Coeptis Pharmaceuticals. CEO Dave Mehalick emphasized that the new name and symbol reflect a period of growth and aim to unlock shareholder value. Coeptis is working on advancing its product portfolio and forming partnerships to enhance its drug development capabilities.
Coeptis Pharmaceuticals (OTC PINK: NDYN) has entered into two exclusive option agreements with VyGen-Bio for co-development rights to innovative technologies targeting CD38-related cancers. The agreements focus on CD38-GEAR-NK, a cell therapy enhancing NK cell resilience against monoclonal antibodies, and CD38-Diagnostic, an in vitro tool for patient suitability assessment for anti-CD38 therapies. Both technologies could significantly impact treatment paradigms for cancers like multiple myeloma. Coeptis must exercise these options by December 31, 2021.
